Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

About Karyopharm Therapeutics

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KPTI
  • CUSIP:
Key Metrics:
  • Previous Close: $11.13
  • 50 Day Moving Average: $10.44
  • 200 Day Moving Average: $9.27
  • 52-Week Range: $5.85 - $11.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.00
  • P/E Growth: 0.26
  • Market Cap: $459.03M
  • Outstanding Shares: 41,243,000
  • Beta: 4.49
Profitability:
  • Return on Equity: -64.20%
  • Return on Assets: -58.62%
Debt:
  • Current Ratio: 8.71%
  • Quick Ratio: 8.71%
Additional Links:
Companies Related to Karyopharm Therapeutics:

Analyst Ratings

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $16.05 (44.20% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetDetails
12/7/2016WedbushReiterated RatingOutperform$14.00View Rating Details
12/4/2016Jefferies Group LLCReiterated RatingBuy$12.00 -> $14.00View Rating Details
11/8/2016Canaccord GenuityReiterated RatingBuyView Rating Details
11/8/2016HC WainwrightReiterated RatingBuyView Rating Details
10/7/2016Leerink SwannReiterated RatingOutperform$18.00View Rating Details
9/6/2016Robert W. BairdReiterated RatingPositive$16.00View Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 -> $7.55View Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$13.00View Rating Details
3/15/2016Bank of America CorpDowngradeNeutral -> Underperform$26.00 -> $11.00View Rating Details
3/14/2016J P Morgan Chase & CoLower Price TargetOverweight$20.00 -> $19.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00View Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00View Rating Details
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00View Rating Details
3/17/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$53.00View Rating Details
(Data available from 2/28/2015 forward)

Earnings

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q316($0.81)($0.69)ViewListenView Earnings Details
8/4/2016Q216($0.76)($0.84)ViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)ViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)ViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)ViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)ViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)ViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)ViewListenView Earnings Details
11/10/2014Q314($0.52)($0.61)ViewN/AView Earnings Details
8/7/2014Q214($0.50)($1.02)ViewN/AView Earnings Details
5/7/2014($0.47)($0.46)ViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
Current Year EPS Consensus Estimate: $-2.93 EPS
Next Year EPS Consensus Estimate: $-2.78 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.79)($0.73)($0.75)
Q2 20163($0.76)($0.73)($0.74)
Q3 20163($0.83)($0.75)($0.79)
Q4 20163($0.69)($0.61)($0.65)
Q1 20171($0.62)($0.62)($0.62)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.64)($0.64)($0.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Ownership Percentage: 14.79%
Institutional Ownership Percentage: 56.97%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2016Ran FrenkelInsiderSell3,309$10.06$33,288.54View SEC Filing  
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
DateHeadline
News IconWhat is the Street Saying About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Aiken Advocate (NASDAQ:KPTI)
aikenadvocate.com - February 25 at 8:28 AM
News IconTracking the Numbers for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Midway Monitor (NASDAQ:KPTI)
midwaymonitor.com - February 25 at 12:28 AM
News IconKaryopharm Therapeutics Inc KPTI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KPTI)
www.bioportfolio.com - February 23 at 11:12 PM
News IconAnalysts Take: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:KPTI)
aikenadvocate.com - February 18 at 9:57 AM
News IconABR Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock At 1.5 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - February 17 at 1:14 PM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) likely to see bigger moves on its earnings reaction day - Post Analyst (NASDAQ:KPTI)
postanalyst.com - February 8 at 5:32 AM
News IconStock Ticking Lower Heading Into The Open: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Aiken Advocate (NASDAQ:KPTI)
aikenadvocate.com - February 2 at 6:55 PM
realistinvestor.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) EPS Projection At $-0.695 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - January 31 at 7:03 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Wall Street Beacon (NASDAQ:KPTI)
wsbeacon.com - January 31 at 7:03 PM
finance.yahoo.com logoKaryopharm to Participate in Upcoming Investor Conferences (NASDAQ:KPTI)
finance.yahoo.com - January 31 at 7:03 PM
News IconConsensus Estimates on Earnings & Stock Price in Focus for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares - Aiken Advocate (NASDAQ:KPTI)
aikenadvocate.com - January 26 at 7:59 PM
biz.yahoo.com logoKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:KPTI)
biz.yahoo.com - January 26 at 7:59 PM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Projected EPS At $-0.65 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - January 24 at 11:55 PM
realistinvestor.com logoEPS Projection Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At $-0.695 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - January 24 at 6:55 PM
News IconEarnings in Full Force, Analysts Take Aim at Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Wall Street Beacon (NASDAQ:KPTI)
wsbeacon.com - January 24 at 6:55 PM
marketnewsvideo.com logoNoteworthy Monday Option Activity: AAP, LPSN, KPTI (NASDAQ:KPTI)
www.marketnewsvideo.com - January 23 at 6:28 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Aiken Advocate (NASDAQ:KPTI)
aikenadvocate.com - January 22 at 6:01 PM
News IconTrading Indicator Check on Karyopharm Therapeutics Inc (KPTI) - Sherwood Daily (NASDAQ:KPTI)
sherwooddaily.com - January 20 at 9:32 PM
News IconTracking CCI Levels on Shares of Karyopharm Therapeutics Inc (KPTI) - Sherwood Daily (NASDAQ:KPTI)
sherwooddaily.com - January 17 at 6:34 PM
News IconWill The Needle Move For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:KPTI)
wsbeacon.com - January 17 at 12:07 PM
News IconStock ABR Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 1.5 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - January 14 at 5:34 AM
realistinvestor.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) EPS Estimate At $-0.695 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - January 11 at 11:50 PM
biz.yahoo.com logoKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:KPTI)
biz.yahoo.com - January 9 at 6:58 PM
investornewswire.com logoSentiments And Ratings Alert: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - January 6 at 11:52 PM
News IconStock ABR Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 1.5 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - January 5 at 7:30 PM
News IconProjected EPS Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At $-0.65 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - January 5 at 5:06 AM
finance.yahoo.com logoKaryopharm to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:KPTI)
finance.yahoo.com - January 3 at 11:17 AM
realistinvestor.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Post EPS Of $-0.695 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - January 2 at 6:07 PM
News IconTop Stock With Upside & Growth Potential: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Prospect Journal (NASDAQ:KPTI)
prospectjournal.com - January 2 at 6:07 PM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Stock ABR At 1.5 ... - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - December 22 at 11:31 PM
investornewswire.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - December 22 at 6:29 PM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Under Analyst ... - UK Market News (NASDAQ:KPTI)
www.ukmarketnews.co.uk - December 22 at 6:28 PM
News IconEquity Rundown: RSI and CCI Check on Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 21 at 7:02 PM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Projected to Achieve EPS Of $-0.65 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - December 21 at 6:31 AM
News IconQuick Review on Trend Indicator Levels: Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 21 at 6:31 AM
News IconStock Momentum in Focus on Shares of Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 17 at 4:50 AM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Awarded $900K Grant from the Target ALS Foundation (NASDAQ:KPTI)
www.streetinsider.com - December 15 at 11:51 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Awarded $900K Grant from the Target ALS Foundation - StreetInsider.com (NASDAQ:KPTI)
www.streetinsider.com - December 15 at 6:51 PM
finance.yahoo.com logoKaryopharm and Collaborators Awarded Grant for ALS Research (NASDAQ:KPTI)
finance.yahoo.com - December 15 at 6:51 PM
finance.yahoo.com logo7:31 am Karyopharm Therapeutics receives $900K in research funding over a two-year period to support preclinical studies of KPT-350 in ALS from the Target ALS Foundation (NASDAQ:KPTI)
finance.yahoo.com - December 15 at 6:51 PM
insidermonkey.com logoDo Hedge Funds Love Karyopharm Therapeutics Inc (KPTI)? (NASDAQ:KPTI)
www.insidermonkey.com - December 14 at 6:51 PM
News IconTechnical Buzz on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - The Business Journal (NASDAQ:KPTI)
belmontbusinessjournal.com - December 12 at 11:22 PM
News IconWhat Are the Technicals Saying About These Shares: Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 12 at 11:22 PM
benzinga.com logo(NOVN), Karyopharm Therapeutics (NASDAQ:KPTI) - Novan CEO ... - Benzinga (NASDAQ:KPTI)
www.benzinga.com - December 11 at 10:12 AM
News IconTechnical Study: Following Indicators for Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 11 at 10:12 AM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Stock ABR At 1.5 - Stock Observer (NASDAQ:KPTI)
www.thestockobserver.com - December 9 at 9:37 AM
News IconSorting Out the Technicals on Shares of Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 7 at 3:22 PM
finance.yahoo.com logoCan Karyopharm Therapeutics (KPTI) Run Higher on Strong Earnings Estimate Revisions? (NASDAQ:KPTI)
finance.yahoo.com - December 7 at 10:21 AM
News IconADX Update on These Shares: Karyopharm Therapeutics Inc (KPTI) - Yankee Analysts (NASDAQ:KPTI)
yankeeanalysts.com - December 6 at 5:57 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Presents Strong Selinexor Phase 2b Data in Certain Multiple Myeloma - StreetInsider.com (NASDAQ:KPTI)
www.streetinsider.com - December 6 at 5:57 PM

Social

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Where is Karyopharm Therapeutics' stock going? Where will Karyopharm Therapeutics' stock price be in 2017?

10 analysts have issued 1-year price objectives for Karyopharm Therapeutics' shares. Their predictions range from $7.55 to $28.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $16.05 in the next twelve months.

When will Karyopharm Therapeutics announce their earnings?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:

  • According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (12/7/2016)

  • Jefferies Group LLC analysts commented, "We believe evolving efficacy/safety data, coupled with mgmt's expertise in the disease area and the continuing unmet need, increases the likelihood (our POS increases to 55 percent from 30 percent) Selinexor will ultimately reach the mkt and generate MM sales of >$500 million by 2025," analyst Brian Abrahams wrote in a note.Near- And Long-Term PositivesMeanwhile, Selinexor is currently in 35 studies exploring multiple tumor types, increasing the potential to optimize indication, dosing and combination. Based on preclinical results, Abrahams believes that data from next-gen XPO1 inhibitor '8602 later this year offer another means to exploit the potential of that agent to target the mechanism with fewer side effects with lower side effects. In addition, the PAK4/NAMPT inhibitor '9274 could potentially broaden the company's long-term opportunity."Though Selinexor's narrow therapeutic window remains the biggest limitation, recent studies (e.g., STOMP) at more optimized doses appear based on our analysis to suggest more acceptable AEs," (8/30/2016)

Who owns Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.47%), Franklin Resources Inc. (7.83%), Palo Alto Investors LLC (7.76%), State Street Corp (0.98%), Dimensional Fund Advisors LP (0.63%) and TCW Group Inc. (0.10%). Company insiders that own Karyopharm Therapeutics stock include Barry E Greene, Justin A Renz, Ltd Chione, Mansoor Raza Mirza and Ran Frenkel.

Who sold Karyopharm Therapeutics stock? Who is selling Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc. and Tudor Investment Corp Et Al. Company insiders that have sold Karyopharm Therapeutics stock in the last year include Ltd Chione and Ran Frenkel.

Who bought Karyopharm Therapeutics stock? Who is buying Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Palo Alto Investors LLC, Russell Investments Group Ltd., Trexquant Investment LP, State Street Corp and Metropolitan Life Insurance Co. NY. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Barry E Greene, Justin A Renz and Ran Frenkel.

How do I buy Karyopharm Therapeutics stock?

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Karyopharm Therapeutics stock cost?

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $11.13.

Karyopharm Therapeutics (NASDAQ:KPTI) Chart for Tuesday, February, 28, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Earnings History Chart

Earnings by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Dividend History Chart

Dividend Payments by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Last Updated on 2/28/2017 by MarketBeat.com Staff